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Abstract 
Introduction: Metabolic syndrome represents a cluster of related metabolic abnormalities, including 
central obesity, hypertension, dyslipidemia, hyperglycemia, and insulin resistance, with central obesity 
and insulin resistance in particular recognized as causative factors. These metabolic derangements 
present significant risk factors for cardiovascular disease, which is commonly recognized as the primary 
clinical outcome, although other outcomes are possible. Metabolic syndrome is a progressive condition 
that encompasses a wide array of disorders with specific metabolic abnormalities presenting at different 
times. These abnormalities can be detected and monitored via serum biomarkers. This review will 
compile a list of promising biomarkers that are associated with metabolic syndrome and this panel can 
aid in early detection and management of metabolic syndrome in high risk populations, such as in West 
Virginia.  
Methods: A literature review was conducted using PubMed, Science Direct, and Google Scholar to 
search for markers related to metabolic syndrome. Biomarkers searched included adipokines (leptin, 
adiponectin), neuropeptides (ghrelin), pro-inflammatory cytokines (IL-6, TNF-α), anti-inflammatory 
cytokines (IL-10), markers of antioxidant status (OxLDL, PON-1, uric acid), and prothrombic factors 
(PAI-1). 
Results: According to the literature, the concentrations of pro-inflammatory cytokines (IL-6, TNF-α), 
markers of pro-oxidant status (OxLDL, uric acid), and prothrombic factors (PAI-1) were elevated in 
metabolic syndrome. Additionally, leptin concentrations were found to be elevated in metabolic syn-
drome as well, likely due to leptin resistance. In contrast, concentrations of anti-inflammatory cytokines 
(IL-10), ghrelin, adiponectin, and antioxidant factors (PON-1) were decreased in metabolic syndrome, 
and these decreases also correlated with specific disorders within the cluster. 
Conclusion: Based on the evidence presented within the literature, the aforementioned biomarkers 
correlate significantly with metabolic syndrome and could provide a minimally-invasive means for early 
detection and specific treatment of these disorders. Further research is encouraged to determine the 
efficacy of applying these biomarkers to diagnosis and treatment in a clinical setting. 
Key words: Metabolic syndrome, literature review 
Introduction 
Metabolic syndrome is a cluster of metabolic 
abnormalities which confers upon an individual a 
substantial increase in cardiovascular disease (CVD) 
risk - approximately twice as high as those without 
the syndrome. Compared to those without metabolic 
syndrome, those with it are at an increased risk of 
mortality from CVD, coronary heart disease, stroke, 
vascular dysfunction, and all-cause mortality [1]. 
While the pathogenesis of metabolic syndrome and its 
components is not well understood, central obesity 
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and insulin resistance are recognized as causative 
factors. Several different organizations have outlined 
diagnostic criteria for metabolic syndrome, which 
designates values for obesity (waist circumference or 
BMI), triglyceride levels, HDL (High Density Lipo-
protein) levels, hypertension, 
hyperglycemia, and sometimes 
urine albumin or albumin: creati-
nine ratio (Table 1). Based on 
AHA criteria, nearly 35% of US 
adults, and 50% of those older 
than 60 years old, have metabolic 
syndrome [2]. Regardless of 
which criteria are used, the pri-
mary concern is early detection of 
potential CVD complications and 
early intervention [3, 4].  
Though the NCEP ATP III 
report and WHO have both iden-
tified CVD as the primary clinical 
outcome of metabolic syndrome, 
most people with metabolic syn-
drome will have insulin re-
sistance, which results in in-
creased risk for type 2 diabetes 
(Figure 1). Once diabetes becomes 
clinically apparent, CVD risk rises 
sharply. In addition to CVD and 
type 2 diabetes, individuals with 
metabolic syndrome are seem-
ingly more susceptible to other 
conditions, including polycystic ovary syndrome, 
fatty liver, cholesterol gallstones, asthma, sleep dis-
turbances, and some forms of cancer, such as breast, 
pancreatic, colorectal, and prostate [5, 6]. 
 
Table 1: Diagnostic Criteria for Metabolic Syndrome  
 IDF (Obesity + >2) AHA(>3) NCEP ATP III (>3) WHO( Insulin re-
sistance/Diabetes + >2) 
EGIR(hyperinsulinemia 
+ >2) 
Obesity BMI >30kg/m2 or specific 
gender and ethnicity waist 
circumference cutoffs 
Waist circumference for 
males >40in, females>35in 
Waist circumference for males 
>40in, females>35in 
Waist/hip ratio>0.9 in males 
and >0.85 in females or 
BMI>30kg/m2 
Waist circumference for 
males >94cm, fe-
males>80cm 
Elevated Tri-
glycerides  
TG>150mg/dL or treatment of 
this lipid abnormality 
Fasting TG>150mg/dL or 
treatment of this lipid ab-
normality 
TG>150mg/dL or treatment 
of this lipid abnormality 
TG>150mg/dL TG >177mg/dL 
Decreased HDL  HDL <40mg/dL in males and 
<50mg/dL in females or 
specific treatment for this lipid 
abnormality 
HDL<40mg/dL in males and 
<50mg/dL in females or 
treatment for this lipid ab-
normality 
HDL<40mg/dL in males and 
<50mg/dL in females or 
treatment for this lipid ab-
normality 
HDL<35mg/dL in males and 
<39mg/dL in females 
HDL< 39 mg/dL 
Hypertension SBP >130 or DBP >85 mm Hg 
or treatment of previously 
diagnosed hypertension 
BP>130/85mm Hg or taking 
medication for hypertension 
SBP >130 or DBP >85 mm Hg 
or taking medication for 
hypertension 
>140/90mm Hg >140/90mm Hg or 
taking medication for 
hypertension 
Hyperglycemia Fasting plasma glucose 
>100mg/dL or previously 
diagnosed type 2 diabetes 
Fasting glucose >100mg/dL 
or taking medicine for high 
glucose 
Fasting glucose >100mg/dL 
or taking medicine for high 
glucose 
Insulin resistance required Insulin resistance re-
quired(plasma insulin 
>75th percentile) 
Other    Urine albumin > 20µg/min or 
Albumin: creatinine ratio > 
30mg/g 
 
IDF- International Diabetes Federation, AHA- American Heart Association, NCEP ATP III- National Cholesterol Education Program-Adult Treatment Panel III, WHO- 
World Health Organization, EGIR- European Group for the Study of Insulin Resistance, BMI- Body Mass Index, SBP – Systolic Blood pressure, DBP- Diastolic Blood Pres-
sure, BP – Blood Pressure, TG- Triglycerides, HDL-High Density Lipoprotein  
 
 
 
Figure 1: Interaction of adipokines, cytokines, and inflammatory markers that contribute 
to the development of metabolic syndrome and its complications. HTN-Hypertension, 
NAFLD/NASH- Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis  
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 Based on “The state of obesity: 2014 report”, 
West Virginia ranks highest in the country for obesity 
prevalence (35.1%) in the adult population. WV is also 
highest-ranked for prevalence of hypertension (41%), 
and ranked second for prevalence of diabetes (13%) in 
the adult population. Given the extent of disease 
burden in our state, it can be inferred that West Vir-
ginia also has one of the highest prevalences, if not the 
highest, of metabolic syndrome and subsequent com-
plications, though no epidemiological data is availa-
ble through a literature search on PubMed. It is im-
perative to find a way to decrease these complica-
tions, and early detection is paramount to this pro-
cess, yet frequently diagnosis is only possible once 
complications have already begun. 
 Research shows that adipocytes produce bioac-
tive substances, known as adipocytokines or adi-
pokines. Accumulation of adipocytes leads to the 
dysregulated production of adipokines, which con-
tributes to the development of metabolic syndrome 
[7]. The list of these dysregulated adipokines and cy-
tokines is constantly growing and is a reflection of the 
heterogeneity of adipose tissue due to the number of 
resident cell types [8].  
The mechanism by which adipose accumulation 
elucidates dysregulation is not entirely clear at this 
time, but some suggest that it is at least partly due to 
systemic oxidative stress brought on by obesity [9]. 
One proposed mechanism by which obesity produces 
oxidative stress is mitochondrial and peroxisomal 
oxidation of fatty acids, which can generate reactive 
oxygen species (ROS) in oxidation reactions. 
Malondialdehyde (MDA), a lipid peroxidation end 
product, is increased in conditions marked by obesity 
and insulin resistance. It is able to enhance expression 
of pro-inflammatory cytokines, resulting in systemic 
stress [10]. In addition to MDA, F-2 isoprostanes 
(F2-IsoPs) are also a product of polyunsaturated fatty 
acid peroxidation. A study has shown that BMI is 
significantly correlated with the F2-IsoP concentra-
tion. Another marker of oxidative stress is urinary 
8-iso prostaglandin F2α (8-iso PGFα). It has been 
shown to be positively correlated with obesity and 
insulin resistance [11].  
 For many pathological states, medicine relies on 
biomarkers to aid in diagnosis and management 
when overt clinical signs or gross anatomic abnor-
malities are absent or are not obvious. In addition to 
this, biomarkers can identify individuals within a 
population susceptible to disease on the basis of a 
“genotype” rather than on a reported history. Bi-
omarkers also afford the ability to quantify this sus-
ceptibility, allowing for an estimation of disease risk 
for a population [12].  
A panel of metabolic syndrome biomarkers 
could provide a relatively easy, minimally-invasive 
means of identifying those who are at risk for devel-
oping metabolic syndrome and subsequent complica-
tions. A panel, rather than just individual biomarkers, 
would be useful since biomarkers can have multiple 
roles and pathways in which they are involved, so it 
would be difficult to say that one biomarker alone is 
sensitive and specific for the diagnosis of metabolic 
syndrome. Furthermore, many of these biomarkers 
are interrelated in how they play a role in metabolic 
syndrome, so correlations between biomarkers would 
be helpful to assess patients. With this early detection, 
early intervention is also possible and could be an 
effective means to diminish the widespread effects 
this syndrome has on the West Virginian population, 
as well as on others. A panel could also provide a 
mechanism to personalize treatment given the etiol-
ogy differences amongst individuals. While there are 
numerous articles listing the biomarkers, both estab-
lished and emerging, this review will compile a panel 
of the most researched biomarkers and provide evi-
dence of their relation to metabolic syndrome. This 
panel could provide a way to diagnose, risk stratify, 
monitor and potentially treat individuals at the mo-
lecular level.  
Methods 
A literature review was performed using Pub-
Med, Science Direct, and Google Scholar from com-
mencement to present and last search was done Au-
gust 25, 2015. All databases were searched for the 
following keywords in varying combinations: “bi-
omarkers”, “metabolic syndrome”, “leptin”, “adi-
ponectin”, “uric acid”, “leptin/adiponectin ratio”, 
“plasminogen activator one”, “Interleukin 6 (IL-6)”, 
“Interleukin 10 (IL-10)”, “ghrelin”, “tumor necrosis 
factor(TNFα)”, “paraoxonase”, “oxidized LDL”, 
“weight loss”, and “medications”. 
Results 
Leptin 
Leptin is an adipokine, which under normal 
physiological conditions functions to reduce appetite, 
increase energy expenditure, increase sympathetic 
activity, facilitate glucose utilization, and improve 
insulin sensitivity [13]. It is expressed in levels pro-
portionate to adipose mass, and though it is produced 
mostly by adipocytes, it is also produced by vascular 
smooth muscle cells, cardiomyocytes, and placenta in 
pregnant women. The functional leptin receptor is in 
the hypothalamus where it functions to increase en-
ergy expenditure and reduce appetite. The receptor is 
also found in other organs such as the heart, liver, 
kidneys, and pancreas; it is also present in the smooth 
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muscle and endothelium of heart, brain vasculature, 
and myometrium [14]. Given the wide range of tar-
gets for leptin based on receptor locations, the effects 
of it are also widespread. Leptin has a functional re-
ceptor, Ob-Rb, in the myocardium, and studies have 
shown a direct link between leptin and myocardial 
structural remodeling [15]. There is controversy as to 
whether leptin causes or protects from left ventricular 
hypertrophy (LVH) as research has shown mixed re-
sults, though more suggest it contributes to LVH [14, 
16]. Independent of conventional risk factors, studies 
have shown that leptin can predict myocardial infarc-
tion [17]. Leptin also affects vascular structure by 
promoting hypertension, angiogenesis, and athero-
sclerosis [14].  
Leptin’s role as a biomarker for metabolic syn-
drome has been researched in different populations. 
Regardless of which demographic studied, elevated 
leptin levels are associated with metabolic syndrome. 
This is not surprising given that elevated leptin is 
associated with obesity, insulin resistance, myocardial 
infarction, and congestive heart failure [14]. Yoshina-
ga et al found that leptin was the most sensitive 
marker for predicting metabolic syndrome (and car-
diovascular risk) in elementary school children [18]. 
Lee et al found that leptin was elevated in postmen-
opausal women with metabolic syndrome. They 
found a positive correlation with leptin and ab-
dominal obesity (one of the components of metabolic 
syndrome), and with the number of components of 
metabolic syndrome present [19]. A study of a Leba-
nese population, which focused on nondiabetic males 
over fifty years old, also found elevated leptin levels 
associated with metabolic syndrome. This study 
found that leptin was strongly correlated with waist 
size, but was only weakly correlated with lipid pro-
file, which disappeared with BMI adjustment [20]. 
Similar findings of elevated leptin associated with 
metabolic syndrome, independent of BMI, were found 
in a Korean population. In this study by Yun et al, 
serum leptin levels increased as the components of 
metabolic syndrome increased, regardless of obese 
and nonobese weight status, implying that reduction 
of leptin levels may be protective, regardless of 
weight loss [21]. Contrary to this, Martins et al, found 
a direct positive association between leptin and obe-
sity, hyperinsulinemia and insulin resistance, but was 
only weakly related to other components of metabolic 
syndrome [22]. Though there is some dissension in the 
literature about whether leptin is associated with 
metabolic syndrome independent of BMI, the general 
consensus is that it is elevated in metabolic syndrome 
in children, the elderly, females, and males, and 
therefore can serve as an effective biomarker on a 
screening panel.  
Adiponectin 
 Adiponectin, like leptin, is an adipose-derived 
plasma protein with widespread effects. However, 
unlike leptin, it is secreted exclusively from adipo-
cytes [23]. The different forms of adiponectin include 
low molecular weight trimer, middle molecular 
weight hexamer, and high molecular weight (HMW). 
The HMW form is believed by many to be the more 
active form and has the most favorable metabolic ef-
fects on insulin sensitization and protection against 
diabetes [14, 23, 24]. Adiponectin has many functions, 
including anti-atherogenesis, insulin sensitization, 
lipid oxidation enhancement, and vasodilatation. 
Therefore, it stands to reason that it is related to met-
abolic syndrome given its impact on all of these 
components. It suppresses almost all processes in-
volved in atherosclerotic vascular change: the expres-
sion of adhesion molecules in vascular endothelial 
cells, adhesion of monocytes to endothelial cells (via 
TNF-α inhibition), vascular smooth muscle cell pro-
liferation and migration, and foam cell formation (via 
oxidized LDL (OxLDL) inhibition) [25]. It has insu-
lin-sensitizing activities, with high levels exerting a 
protective effect against type 2 diabetes in diabe-
tes-prone individuals [7] and low levels being an in-
dependent risk factor for future development of type 
2 diabetes [26]. Levels of adiponectin are low in sub-
jects with essential hypertension and in the obese, but 
adiponectin levels can be increased with weight loss 
[7, 27].  
 A study of Japanese adults by Ryo et al showed 
that adiponectin levels were negatively correlated 
with waist circumference, visceral fat, serum triglyc-
erides, fasting plasma glucose, fasting plasma insulin, 
and systolic and diastolic blood pressure in males and 
females, and positively correlated with HDL. As the 
mean number of metabolic syndrome components 
increased, plasma adiponectin levels decreased. They 
found that men had lower levels of adiponectin than 
women, which is interesting since it may be part of the 
reason why women have a lower risk of coronary 
artery disease [7]. Gannage et al found adiponectin to 
be inversely correlated with metabolic syndrome, 
independent of BMI as other studies have also shown 
in the past [20, 28]. Santaneimi et al studied a Finnish 
population and found decreasing adiponectin levels 
correlated with an increasing number of components 
of metabolic syndrome in both sexes, and this was 
once again independent of BMI [27]. Overall, the lit-
erature shows that adiponectin is inversely related to 
metabolic syndrome and the number of components 
present. However, many believe HMW adiponectin to 
be the more active form and Falahi et al suggest that 
HMW adiponectin may even be the most reliable 
biomarker for metabolic syndrome diagnosis [29]. 
Int. J. Med. Sci. 2016, Vol. 13 
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Hara et al found that the ratio of HMW adiponectin to 
plasma adiponectin was an even better predictor of 
insulin resistance and metabolic syndrome [30]. 
Therefore, adiponectin, and preferably HMW adi-
ponectin, should be considered on a panel of bi-
omarkers for metabolic syndrome diagnosis.  
Leptin: Adiponectin Ratio  
Other studies have determined that the leptin: 
adiponectin ratio (LAR) is more beneficial than either 
alone. Falahi et al showed that a high LAR is a better 
biomarker than leptin or adiponectin alone for the 
diagnosis of metabolic syndrome [29]. A study of 
Japanese patients found that LAR was significantly 
and positively associated with the number of com-
ponents of metabolic syndrome present, and the ratio 
was independently associated with each component 
of metabolic syndrome [31]. However there may be 
differences to this between males and females. Cicero 
et al found the LAR to be strongly associated with 
metabolic syndrome, especially in males. The associa-
tion was weaker in females since they had more ele-
vated adiponectin levels, which is thought to be pro-
tective against metabolic syndrome [32]. Others pos-
tulate that the ratio difference between males and 
females is due to the difference in glucose and lipid 
metabolism [31]. One limiting factor with using just 
adiponectin or leptin is that the difference between 
adiponectin and leptin tends to be small in the fasting 
vs postprandial state. Therefore, one of the benefits of 
using the LAR is that it has the potential to assess in-
sulin sensitivity and metabolic syndrome in the non-
fasting state [33]. 
Ghrelin  
Ghrelin is a neuroendocrine hormone secreted 
primarily by the stomach that stimulates appetite di-
rectly via activation of the GH secretagogue receptor 
1a (GHSR-1a) in the hypothalamus, and indirectly by 
increasing expression of orexigenic peptides, such as 
neuropeptide Y (NPY) [34, 35]. It may also be protec-
tive of vasculature by antagonizing the effects of vas-
oconstrictors, such as endothelin 1, and promoting the 
effects of vasodilators, such as nitric oxide (NO) [36]. 
Furthermore, it can help to promote lipolysis via 
stimulation of hypothalamic AMP-activated protein 
kinase (AMPK) [35]. Research into the vasoprotective 
and lipolytic properties of ghrelin is emerging and 
presents two pathways by which ghrelin can exert a 
protective effect against metabolic syndrome.  
Metabolic syndrome is associated with lower 
levels of ghrelin, and progressively lower ghrelin lev-
els are associated with increasing metabolic syndrome 
severity. Ghrelin levels decrease with increasing 
number of metabolic syndrome derangements [37-40]. 
This trend is significant even after adjusting for age 
and sex, though ghrelin levels have been shown to be 
higher in females than males [37, 38]. Low ghrelin 
levels have been associated with the components of 
metabolic syndrome including obesity, insulin re-
sistance, and hypertension [41-43]. However the as-
sociation between low ghrelin and metabolic syn-
drome is likely primarily explained by the relation-
ship to obesity as obese patients with metabolic syn-
drome have lower ghrelin levels than nonobese 
counterparts [44]. Furthermore, amongst obese pa-
tients, ghrelin levels are lower in insulin resistant pa-
tients compared to insulin sensitive obese patients 
[45]. Plasma ghrelin levels are also decreased in the 
healthy offspring of type 2 diabetes patients suggest-
ing a genetic component to ghrelin regulation [37]. 
Ghrelin is implicated in endothelial function by pre-
venting proatherogenic changes and improving vas-
odilation [37]. Tesauro et al assessed vascular function 
by measuring forearm blood flow in metabolic syn-
drome and control patients. They showed that exog-
enous ghrelin significantly reduced the vasoconstric-
tor effects of endothelin 1 and enhanced the vasodi-
lator effects of NO in metabolic syndrome patients, 
but did not have a significant effect on vascular tone 
in control patients [36]. Given ghrelin’s relation to 
each of the components of metabolic syndrome, to 
metabolic syndrome itself, and the potential to note 
abnormal levels in healthy individuals with genetic 
predispositions, it would be an effective biomarker for 
metabolic syndrome.  
Plasminogen Activator Inhibitor – 1 
Plasminogen Activator Inhibitor-1 (PAI-1) is the 
primary of four serine peptidase inhibitors that func-
tions to modulate extracellular matrix remodeling and 
fibrinolysis. It binds to and deactivates tissue plas-
minogens (tissue type plasminogen activator (tPA), 
urokinase plasminogen activator (uPA)). tPA is 
thought to be responsible for intravascular plasmin-
ogen activation, with fibrin regulating its activity, and 
uPA is responsible for plasminogen activation on mi-
grating cells, with the uPA receptor regulating its ac-
tivity on different cells. Thus, PAI-1 can inhibit intra-
vascular fibrinolysis and cell-associated proteolysis 
[46].  
 Under physiologic conditions, PAI-1 is secreted 
into the circulation or extracellular space by endothe-
lial cells, adipocytes, vascular smooth muscle cells, 
platelets, or hepatocytes. Under pathologic conditions 
however, PAI1 is induced by many pro-inflammatory 
and pro-oxidant factors. For example, when TNF-α, 
transforming growth factor beta (TGF-β), angiotensin 
II, glucocorticoids, and insulin are elevated, adipo-
cytes are stimulated to increase PAI-1 levels. Hypoxia 
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and ROS also increase PAI-1 levels. Elevated levels of 
PAI-1 consequently effect vasculature, inflammatory 
signaling, adiposity, and insulin resistance [47].  
Aberrant PAI-1 levels are associated with several 
pathological diseases. For example, high levels are 
positively correlated with thrombotic vascular condi-
tions such as myocardial infarction and deep vein 
thrombosis. This is thought to be related to the inhi-
bition of fibrin degradation and vessel wall remodel-
ing. It is thought to be a strong risk factor for coronary 
artery disease and some suggest it can be used as an 
independent risk factor for cardiovascular risk [48, 
49]. It has also been implicated in cancer angiogenesis 
and metastasis, wound healing, bacterial infections, 
rheumatoid arthritis, and chronic kidney disease [50].  
  The link between PAI-1 and metabolic syn-
drome has been long established with elevated levels 
being strongly correlated such that the more severe 
the metabolic syndrome, the higher the PAI-1 [51-53]. 
Kraja et al showed that PAI-1 was strongly associated 
with the components of metabolic syndrome, includ-
ing BMI, triglycerides and insulin resistance [47]. In-
terestingly, several groups have found that PAI-1 
levels are not associated with dyslipidemia but rather 
with the distribution phenotype of adipocytes: vis-
ceral adipose tissue primarily and ectopic fat in the 
liver [54, 55]. Given this, some suggest PAI-1 can serve 
as a biomarker for ectopic fat storage. Like several of 
the other metabolic syndrome biomarkers, differences 
between the sexes have been noted, with the rela-
tionship being stronger in males than females [55]. 
PAI-1 levels decrease with calorie restriction, weight 
loss, decrease in body fat, and when insulin resistance 
improves [46, 56]. Treatment with insulin-sensitizing 
drugs decreases PAI-1 in patients with diabetes and to 
some extent in otherwise healthy obese individuals 
[57].  
Uric Acid  
Uric acid is an endogenously produced terminal 
degradation product of purine catabolism, formed by 
the liver and excreted by the kidneys primarily and 
intestines secondarily. Uric acid has antioxidant ca-
pacities extracellularly and can be responsible for 2/3 
of the total plasma antioxidant capacity, where it 
chelates metals and scavenges oxygen radicals. 
However, intracellularly, it has pro-inflammatory and 
pro-oxidant activity. It has been shown that uric acid 
is a circulating marker for oxidative damage in condi-
tions like ischemic liver, atherosclerosis, diabetes, and 
chronic heart failure [58]. As a pro-oxidant, under 
ischemic conditions or as a result of tissue damage, 
uric acid oxidizes lipids, which results in inflamma-
tion that disrupts reverse cholesterol transport [59]. It 
also decreases the availability of nitric oxide, which 
results in less vasodilation and more reactive oxygen 
species (ROS). This, coupled with its ability to stimu-
late monocytes to produce TNF-α, creates a 
pro-inflammatory state found in metabolic syndrome. 
Though its role in pathological diseases is not com-
pletely understood, uric acid likely causes systemic 
inflammation [58]. 
Hyperuricemia is a well-known risk factor for 
atherosclerotic events like myocardial infarction and 
stroke, and is associated with other cardiovascular 
risk factors like hypertension and dyslipidemia. Ishi-
zaka et al also found a positive correlation between 
uric acid and BMI, blood pressure, and triglycerides, 
and a negative correlation with HDL-C [60]. Silva et al 
shows that uric acid levels are significantly elevated in 
males with abdominal obesity and females with ab-
dominal obesity, low HDL-C, and hypertension [61]. 
It is also suggested that hyperuricemia is a marker of 
insulin resistance, as some studies have shown that 
decreasing insulin resistance by diet or medications 
decreases uric acid levels [62-64]. Among dietary 
causes of hyperuricemia, excess consumption of 
fructose via added sucrose or high-fructose corn syr-
up is of particular interest, as this dietary component 
has also been implicated in metabolic syndrome. Ac-
cording to Khitan and Kim, fructose metabolism is 
initiated by an enzyme called ketohexokinase (KHK), 
also known as fructokinase. This ATP-dependent step 
in fructose metabolism lacks a negative feedback 
mechanism, so in the event of excessive fructose 
consumption, ATP is rapidly depleted and many of 
the dephosphorylated adenosine compounds are 
catabolized, resulting in increased uric acid [65]. 
Johnson et al demonstrated a link between fruc-
tose-induced hyperuricemia and an increased inci-
dence of metabolic syndrome and some of its features, 
including obesity, hypertension, and insulin re-
sistance [66]. 
 Given the relation of uric acid and all the com-
ponents of metabolic syndrome, it is expected that 
uric acid would be elevated for metabolic syndrome 
as a whole as well. Ishizaka et al investigated the re-
lationship between uric acid and metabolic syndrome 
and found there to be a graded increase in the preva-
lence of metabolic syndrome with increasing uric acid 
in both sexes, though there are differences in the lev-
els between males and females [60]. Levels of uric acid 
increase with age: in women of childbearing age, lev-
els are lower, but increase to similar levels as males 
when postmenopausal [67]. Several studies have 
shown that uric acid levels are significantly elevated 
in individuals with metabolic syndrome, increases 
with the number of components of the condition, and 
is an indicator of worse cardiovascular risk profile [61, 
68, 69]. It is estimated that individuals with a high uric 
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acid have an odds ratio of 1.6-fold higher for devel-
oping metabolic syndrome [70]. The close relationship 
between uric acid and the presence of metabolic syn-
drome has been demonstrated in children, adoles-
cents, and adults [71].  
Through a search of the published literature to 
date, uric acid appears to be the only metabolic syn-
drome biomarker studied in the West Virginian pop-
ulation. Soukup et al studied salivary uric acid as a 
biomarker for metabolic syndrome and found the 
relationship to metabolic syndrome and each of its 
components similar to that of serum uric acid [72]. 
Similar to other studies, Soukup et al noted a stronger 
association between uric acid levels and metabolic 
syndrome in females than in males [72-74]. This is a 
noninvasive and cost-effective method to diagnose 
and monitor metabolic syndrome and its components 
in rural locations, like West Virginia, where health 
care capabilities are limited.  
Interleukin-6 
Interleukin-6 (IL-6) is a pro-inflammatory cyto-
kine that plays a role in the natural inflammatory re-
sponse. It is often secreted by M1 macrophages as part 
of the normal inflammatory response against infection 
and injury [75]. In metabolic syndrome, adipocyte 
dysfunction is frequently present and is associated 
with an increase in M1 macrophage population within 
adipose tissue. This can result in increased secretion 
of IL-6 and other pro-inflammatory cytokines from 
adipose tissue. These pro-inflammatory cytokines can 
then act through a number of cell signaling pathways, 
including mTOR and Protein Kinase C (PKC) to in-
duce insulin resistance. Through its inflammatory 
properties it has been implicated in the endothelial 
cell damage within blood vessels that leads to vascu-
lar dysfunction and atherosclerosis. Furthermore, IL-6 
can cause aberrant insulin receptor activation, result-
ing in abnormal insulin signaling cascades, abnormal 
insulin action, and abnormal glucose metabolism [75]. 
 Studies have shown that elevated levels of IL-6 
are associated with metabolic syndrome and increas-
ing levels are associated with more severe metabolic 
syndrome (assessed by hypertriglyceridemia, hyper-
tension, and fasting glucose levels) [76-78]. Similar to 
other biomarkers, IL-6 is also associated with each of 
the components of metabolic syndrome. In a study on 
postmenopausal women, elevated IL-6 was also asso-
ciated with abdominal obesity, low HDL, and high 
triglycerides [77]. Indulekha et al found elevated IL-6 
was associated with insulin resistance [78]. In vivo 
animal studies have shown the effect of IL-6 on insu-
lin signaling: the administration of IL-6 to mice re-
sulted in impaired insulin signaling in muscle and 
liver tissue, leading to hyperglycemia and insulin 
resistance [79].  
IL-6’s close association with metabolic syndrome 
and each of its components suggests that it is an im-
portant factor in the progression of metabolic syn-
drome and would be a good addition to a biomarker 
panel.  
Tumor Necrosis Factor-Alpha 
Tumor Necrosis Factor-Alpha (TNF-α) is a 
pro-inflammatory cytokine that is secreted by visceral 
adipose tissue, a common characteristic of metabolic 
syndrome [80]. Because metabolic syndrome is often 
characterized by adipocyte dysregulation, and these 
dysregulated adipocytes tend to secrete TNF-α, IL-6, 
and other pro-inflammatory adipokines at higher 
levels, the central obesity often encountered in meta-
bolic syndrome could be a risk factor for elevated 
TNF-α levels [75]. Furthermore, elevated TNF-α levels 
are associated with insulin resistance via its aberrant 
activation of the mTOR and PKC signaling pathways 
[75]. Its contribution to the various characteristics of 
metabolic syndrome suggest that TNF-α may be a 
significant contributor to the development and pro-
gression of its associated disease processes. 
In a study of middle-aged adults with metabolic 
syndrome, elevated levels of TNF-α and other 
pro-inflammatory cytokines were associated with 
insulin resistance and hypertriglyceridemia. The 
TNF-α, IL-6, and leptin levels in these patients were 
higher than those levels in the control group, indicat-
ing that these cytokines directly correlated with met-
abolic syndrome [81]. It was hypothesized by Balasoiu 
et al that early detection of a patient’s inflammatory 
status, including TNF-α and IL-6, could be useful in 
monitoring and early intervention for metabolic syn-
drome and its comorbidities [81]. In another study of 
metabolic syndrome patients with coronary artery 
disease (CAD), TNF-α levels were found to be signif-
icantly higher than the controls [82]. Indulekha et al 
also found elevated TNF-α levels to be significantly 
correlated with the presence of metabolic syndrome, 
and more so in those with insulin resistance [78]. Mu-
sialik et al demonstrated elevated levels of soluble 
TNF-α receptor (sTNFα-R), which is associated with 
increased TNF-α activity, in patients with metabolic 
syndrome with hypertension [80]. Because it exerts 
such widespread systemic effects, TNF-α may con-
tribute to the various disease processes associated 
with metabolic syndrome. 
Interleukin-10 
Interleukin-10 (IL-10) is a predominantly an-
ti-inflammatory cytokine that plays a role in modu-
lating systemic inflammation. Secreted by monocytes 
or M2 macrophages, one of its functions is to help 
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promote normal tissue remodeling following an in-
flammatory response [75]. One of the methods by 
which IL-10 moderates the inflammatory response is 
by inhibiting NADPH oxidase, and therefore the ox-
idative stress resulting from this enzyme. This has 
been associated with aberrant insulin receptor sub-
strate (IRS) activation and impaired insulin signaling. 
Furthermore, the insulin signaling pathway can be 
dysregulated by abnormal levels of the 
pro-inflammatory cytokines IL-6 and TNF-α. IL-10 
can restore normal insulin signaling by inhibiting 
NADPH oxidase-induced oxidative stress or by an-
tagonizing the actions of IL-6 and TNF-α [75, 79].  
Regarding the role IL-10 plays in insulin signal-
ing, a cross-sectional population study of elderly 
adults demonstrated that low levels of IL-10 are asso-
ciated with insulin resistance and type 2 diabetes. 
Furthermore, the study found that IL-10 levels in-
versely correlated with levels of total cholesterol, 
LDL, triglycerides, blood glucose and hemoglobin 
A1c, and positively correlated with HDL levels [83]. 
Additionally, in a study on mice treated with IL-6 to 
induce insulin resistance, in vivo administration of 
IL-10 demonstrated protection from the impaired in-
sulin signaling that resulted from IL-6 administration, 
thereby restoring insulin sensitivity and normal glu-
cose metabolism in liver and muscle tissue [79]. Be-
cause it antagonizes the pro-inflammatory actions of 
IL-6 and TNF-α, which are both associated with met-
abolic syndrome and its comorbidities, IL-10 appears 
to exert a protective effect against increases in these 
cytokines.  
The significance of IL-10 in relation to metabolic 
syndrome as a whole, rather than its components, 
however, is a little more complicated. A study of 
obese children, found IL-10 levels to be elevated in 
metabolic syndrome, even after BMI was taken into 
account. Calcaterra et al proposed the elevated levels 
to be due to the first phase of a complex mechanism in 
the development of metabolic syndrome in children 
[84]. Esposito et al studied obese and nonobese 
women and found IL-10 to be elevated in obese 
women compared to nonobese women but IL-10 lev-
els were significantly lower in both obese and 
nonobese women with metabolic syndrome [85]. 
Others have also shown IL-10 levels to be significantly 
decreased in those with metabolic syndrome in both 
males and females [86, 87]. Some have shown that 
IL-10 levels are significantly correlated with other 
cytokines like IL-6 and TNF-α. Adiponectin is corre-
lated with IL-10 in patients with metabolic syndrome 
and not the general population [88]. This suggests that 
if both IL-10 and adiponectin are low, the risk of 
metabolic syndrome is likely greater. The use of mul-
tiple biomarkers in a panel would likely increase the 
sensitivity and specificity.  
Oxidized LDL 
Oxidized LDL (OxLDL) is a product of lipid ox-
idation and can serve as a marker of oxidative stress. 
Lipid oxidation contributes to the generation of reac-
tive oxygen species (ROS). These products form 
components of OxLDL. Lipid oxidation products, 
ROS, and OxLDL in low concentrations can serve as 
signaling compounds for pathways of cellular anti-
oxidants, including Heme Oxygenase (HO-1) and 
glutathione. However, if the antioxidant capacity of 
the cell is dysfunctional, as is often seen in metabolic 
syndrome, then these compounds contribute to an 
oxidative cascade that eventually leads to cell damage 
and apoptosis [89]. This widespread cell damage and 
death can contribute to the vascular dysfunction 
commonly seen in metabolic syndrome, while the 
dysfunctional OxLDL can further contribute to 
dyslipidemia, presenting a risk factor for cardiovas-
cular diseases, which are common comorbidities as-
sociated with metabolic syndrome. OxLDL contrib-
utes to atherosclerosis by invading and damaging the 
blood vessel endothelium [90]. In addition to cardio-
vascular disease, elevated levels of OxLDL in adults 
are associated with obesity and insulin resistance, two 
common components of metabolic syndrome [91]. 
Studies have shown that levels of OxLDL are 
significantly elevated in metabolic syndrome patients 
and these elevated levels are further associated with 
reduced arterial elasticity, a risk factor for the devel-
opment of CAD [90, 92]. Other studies on children 
associated elevated levels of OxLDL with increased 
adiposity and insulin resistance. This study suggested 
that oxidative stress, measured by OxLDL levels, 
could be a contributing factor to insulin resistance, 
and that these changes can present early in life [91]. 
Additionally, a longitudinal study of young adults 
measured at baseline, 15 years later, and 20 years later 
demonstrated a significant positive correlation be-
tween OxLDL levels and the incidence of metabolic 
syndrome that arose between the 15-year and 20-year 
follow-ups. The study also associated elevated Ox-
LDL levels with central obesity, hyperglycemia, and 
hypertriglyceridemia, all of which are components of 
metabolic syndrome [93]. The literature suggests that 
OxLDL serves not only as a promising biomarker for 
metabolic syndrome detection, but a plausible mech-
anism by which the components of metabolic syn-
drome develop and progress. 
Paraoxonase 
Paraoxonase-1 (PON-1) is a multipurpose anti-
toxic and antioxidant enzyme and is believed to con-
tribute to the antioxidant and anti-inflammatory 
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properties of HDL [94, 95]. In particular, it can reduce 
lipid peroxidation and protect LDL and tissue from 
oxidative stress [96]. Levels of PON-1 activity corre-
late with systemic antitoxic and antioxidant capacity, 
whereas oxidative stress and lipid peroxidation are 
associated with the onset and progression of meta-
bolic syndrome and some of its comorbidities, partic-
ularly vascular dysfunction (resulting from OxLDL) 
[90]. In low concentrations, OxLDL and ROS serve as 
signaling compounds in cellular antioxidant path-
ways, which serve to improve cellular protection 
mechanisms in the face of oxidative stress. However, 
if these antioxidant pathways are overwhelmed from 
excessive oxidative stress, the oxidative cascade can 
progress to cell damage and death, resulting in tissue 
damage, particularly in vascular endothelial tissue 
[89]. Because of its antioxidant properties, PON-1 may 
play a role in managing the normal oxidative signal-
ing pathway, and it could serve as a useful biomarker 
in assessing antioxidant capacity, and by extension, 
the propensity for systemic inflammation and vascu-
lar dysfunction. 
In a study of lean, overweight and obese ado-
lescents, decreased levels of PON-1 were associated 
with central obesity and metabolic syndrome. Addi-
tionally, lower levels of PON-1 were associated with 
hypertension, hypertriglyceridemia, insulin re-
sistance, impaired glucose tolerance, and increased 
oxidative stress [94]. Another study of women with 
and without metabolic syndrome showed a negative 
correlation between PON-1 levels and the presence of 
CAD in metabolic syndrome patients [96]. CAD is a 
significant comorbidity in metabolic syndrome, and 
lower levels of PON-1 could be suggestive of a di-
minished effectiveness of HDL to attenuate CAD de-
velopment and progression. Martinelli et al also 
found that decreased PON-1 levels were associated 
with metabolic syndrome, with an inverse correlation 
between PON-1 levels and the severity of metabolic 
syndrome and its comorbidities [95]. The literature 
suggests that PON-1, via its antioxidant properties, 
could play an important role in attenuating the com-
ponents of metabolic syndrome that arise and pro-
gress as a result of oxidative stress. 
Discussion 
 This paper is an attempt to compile the existing 
literature of biomarkers with the most substantial 
evidence of their relationships to metabolic syndrome. 
Obesity has been classified as a disease state, and this 
is especially true in the state of West Virginia, where 
one of the larger cities, Huntington, was listed in a 
recent CDC report as the most obese in the nation, in 
the most obese developed country based on average 
BMI. Thus, a panel of biomarkers that could be used 
clinically to help predict and establish metabolic syn-
drome in individuals would be of immense value, not 
only in treating those that already have the syndrome, 
but in decreasing the overall prevalence of the disease 
in the general population. While there have been a 
number of studies looking at various cytokines and 
adipokines thought to act as biomarkers for the syn-
drome, a panel that can be used in clinical practice 
does not exist. Some have been shown to have greater 
potential than others, but no single biomarker has 
been shown to be indicative of metabolic syndrome 
alone.  
 Metabolic syndrome is a multifactorial condi-
tion that stems from obesity as the causative factor, 
though the exact mechanism is yet to be determined. 
Many suggest that oxidative stress, the hallmark of 
obesity, is linked to a chronic low-grade inflamma-
tion. The induced systemic oxidative stress is thought 
to be at least partly responsible for the dysregulated 
secretion of adipokines that contributes to metabolic 
syndrome [9]. Hypertrophied adipocytes generate 
high levels of ROS which impacts signaling and 
neighboring perivascular endothelium or resident 
immune cells [97]. This is compounded by ROS pro-
duced from the resultant metabolic derangements 
such as hyperglycemia and dyslipidemia. Overall, 
systemic oxidative stress promotes inflammation, 
results in endothelial dysfunction and altered lipid 
metabolism, and affects insulin sensitivity (Figure 2). 
Leptin, LAR, PAI-1, uric acid, IL-6, TNF-α, and 
OxLDL have all been shown to be elevated in meta-
bolic syndrome, across different populations and 
generally are correlated with the number of compo-
nents of metabolic syndrome present. On the other 
hand, adiponectin, ghrelin, IL-10, and PON-1 have all 
been shown to be decreased in metabolic syndrome 
(Table 2). Some ratios, such as HMW- adiponectin: 
adiponectin and LAR are better predictors than any 
alone. To date, there is no established panel to test for 
metabolic syndrome, but this review has compiled a 
panel of the best candidates. 
Furthermore, utilizing the panel as a means of 
customizing treatment and follow up may be possible 
given that associations have been shown between 
each of the biomarkers and lifestyle modifications and 
medications. Though it is difficult to say whether 
there is a true causal relationship between medica-
tions and alterations of the biomarker levels, these 
associations can at least guide clinicians (Table 2). 
Weight loss, which is already known as a treatment 
for metabolic syndrome, has been shown to result in 
levels of all the biomarkers normalizing. Metformin, 
ACEI, and statins have shown similar effects, alt-
hough data for every single biomarker is not available 
for each of these drugs/drug classes.  
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The potential for using multiple biomarkers for 
diagnosis and early detection, and subsequent cus-
tomization of treatment and risk management, is a 
blossoming field with much room for research. De-
spite there being many studies on individual bi-
omarkers, there is a void in research on the implica-
tions of multiple biomarkers being abnormal. Creat-
ing such a panel could provide a relatively easy and 
minimally-invasive way to detect metabolic syn-
drome and possibly indicate the severity, depending 
on the combination of aberrations. Such a panel 
would be highly useful in locations where metabolic 
syndrome poses a significant burden, such as West 
Virginia.  
 
 
Figure 2: Schematic representation of panel of biomarkers in metabolic syndrome.  
 
Table 2: Biomarker levels in metabolic syndrome and interventions. ACEI- Angiotensin converting enzyme inhibitor; IFNβ- Interferon-β 
Biomarker Source 
 
Metabolic 
Syndrome  
Interventions shown to “normalize” levels 
Lifestyle Modi-
fication 
Antihypertensive Diabetic Lipid Lowering Other 
Leptin Adipocytes 
Cardiomyocyte 
Vascular Smooth 
Muscle 
 Weight loss [98] 
 
1. Hydralazine [99] 
2. Valsartan[100] 
3. Ramipril [98] 
4. Candesartan [98] 
5. Amlodipine[98] 
6. Efonidipine [101] 
7. pindolol [102] 
8. Bunazosin [103] 
9. Methyldopa [99] 
 Metformin [104] 
 
 Bromocriptine [105] 
Adiponectin Adipocytes  Weight loss [106] 
 
Valsartan [107] 
 
1. Metformin [108] 
2. Sitagliptin [109] 
3. Pioglitazone [110] 
4. Troglitazone [111] 
5. Rosiglitazone [112] 
6. Glimeperide [113] 
Atorvastatin 
(increases HMW 
adiponectin) [114] 
 
 
Ghrelin  Stomach   Weight loss [115] 
 
Valsartan [116] 1. Rosiglitazone [117] 
2. Metformin [117] 
 1.Flutamide [118] 
2. Estrogen therapy 
[119] 
PAI-1 Adipocytes 
Hepatocytes  
Smooth muscle 
cells,  
Platelets 
 Weight loss [56] 
 
 
 
1. Imidapril [120] 
2. Candesartan (cannot 
sustain decreased PAI 
>4 weeks) [120] 
1. Metformin [121] 
2. Troglitazone [57] 
 
Statins [122]  Sibutramine [121] 
 
Uric Acid Liver  Weight loss [123] 1. Losartan [124]  1. Metformin [125] 1.Atorvastatin [126]  1.Sibutramine [125] 
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Biomarker Source 
 
Metabolic 
Syndrome  
Interventions shown to “normalize” levels 
Lifestyle Modi-
fication 
Antihypertensive Diabetic Lipid Lowering Other 
 2. Calcium Channel 
Blockers [124] 
3. ACEI [125] 
2.Troglitazone [125] 
 
2.Simvastatin [125] 
3.Fenofibrate [125] 
 
2. Orlistat [125] 
IL-6 M1 macrophage  Weight loss[127] 
 
1.ACEI [128] 
2.Olmesartan [129] 
 
Metformin [130] 1.Atorvastatin [131] 
2.Pravastatin [132] 
3.Simvastatin [133] 
1.Hydrocortisone [134] 
2.Celecoxib [135] 
TNFα Visceral Adipo-
cytes, M1 mac-
rophages 
 Weight loss [127] 
 
Olmesrtan[129] 
 
Metformin [130] 1.Atorvastatin [131] 
2.Pravastatin [132] 
1.Orlistat [127] 
2.Hydrocortisone [134] 
IL-10 Monocytes, M2 
macrophage 
 Weight loss[136] 
 
 Metformin [130] Statins [137] 
 
1.Triamcinolone [138] 
2.Montelukast [138] 
3.IFNβ [139] 
4.Beta 1-3 Glucan [140] 
OxLDL Adipocytes  Weight loss [141] 
Vegan Diet [142] 
Fosinopril [143]  1.Statins [144] 
2.Ezetimibe [145] 
Celecoxib [146] 
PON-1 Liver  Weightloss**(dec
reases pon1) 
[141] 
Eplerenone [147]) 1.Rosiglitazone [148] 
2.Sulfonueras[149] 
1.Fibrates [150] 
2.Statins ([151]) 
3. Probucol [152] 
4.Ezetimibe [145] 
 
 
 
Conclusion  
 Metabolic syndrome is a condition with genetic 
and acquired etiologies that results in CVD complica-
tions in populations across the world, but especially 
in the West Virginian population given the rates of 
obesity, hypertension, and diabetes. Creating a panel 
of biomarkers with a known and predictable associa-
tion with metabolic syndrome can provide a means to 
detect those at risk and intervene as needed. This 
could significantly decrease the burden complications 
impose on patients and the healthcare system. 
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